creatine has been researched along with Diabetic Glomerulosclerosis in 42 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality." | 3.11 | Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. ( Agarwal, R; Ahlers, C; Anker, SD; Brinker, M; Filippatos, GS; Joseph, A; Lambelet, M; Lawatscheck, R; Pitt, B; Rossing, P; Ruilope, LM, 2022) |
| "Diabetic nephropathy is the kidney disease that occurs as a result of diabetes." | 2.94 | Therapeutic effect of Chinese prescription Kangen-karyu in patients with diabetic nephropathy. ( Hiratani, K; Natazuka, T; Park, CH; Yokozawa, T, 2020) |
| "Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease." | 2.73 | Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. ( Bolton, WK; Degenhardt, TP; Khalifah, RG; McGill, JB; Schotzinger, RJ; Williams, ME, 2007) |
| "For patients with left ventricular hypertrophy (LVH), the use of an angiotensin converting enzyme (ACE) inhibitor is known to be effective and well tolerated and to be protective against chronic renal insufficiency (CRI)." | 2.70 | Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy. ( Ikeda, N; Kanno, Y; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H, 2002) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Eighty six patients with Type 2 diabetes mellitus (T2DM) were enrolled for this study." | 1.43 | [Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus]. ( Niu, H; Shen, J; Shi, X; Wang, R; Wang, S; Wu, J; Yang, H; Zhang, Y; Zhou, S, 2016) |
| "Bilirubin treatment also decreased the amount of mesangial matrix, lowered the expression of renal collagen IV and transforming growth factor (TGF)-β1, and reduced the level of apoptosis in the kidney, compared to the DM group." | 1.40 | Effect of bilirubin on triglyceride synthesis in streptozotocin-induced diabetic nephropathy. ( Ahn, SY; Baek, SH; Chae, DW; Chin, HJ; Kim, S; Lee, ES; Na, KY; Xu, J, 2014) |
| "However, the roles of miRs in diabetic nephropathy remain unclear." | 1.39 | Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. ( Gao, Y; Li, M; Ma, M; Wang, J; Yang, J; Zhao, X; Zhu, Z; Zou, D, 2013) |
| "Lumbrokinase treatment attenuated diabetic nephropathy in rats, possibly through increasing the activity of MMPs and the subsequent degradation of extracellular matrix." | 1.39 | Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats. ( Cheng, X; Ge, N; Li, S; Li, Y; Shao, M; Shen, J; Sun, H, 2013) |
| "Treatment with fenofibrate (80 mg/kg/day, p." | 1.38 | The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. ( Balakumar, P; Bishnoi, HK; Mahadevan, N, 2012) |
| "Documented diabetic nephropathy prevalence showed marked variation across practices (range 0-100%) and was significantly negatively correlated with diabetes list size, albumin creatinine ratio testing rates and renin-angiotensin-aldosterone system blockade use and positively correlated with exception reporting rates." | 1.36 | Identifying additional patients with diabetic nephropathy using the UK primary care initiative. ( Cardwell, CR; Fogarty, DG; Hunter, SJ; Kee, F; Magee, GM; Murphy, MC; Savage, G, 2010) |
| "However, diabetic patients with ESRD secondary to dNP were significantly younger than those with vNP." | 1.33 | Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy. ( Biesenbach, G; Janko, O; Pieringer, H; Schmekal, B, 2006) |
| "Although the pathogenetic mechanism of diabetic nephropathy has not been elucidated, an inflammatory mechanism has been suggested to contribute to its progression." | 1.32 | Effect of retinoic acid in experimental diabetic nephropathy. ( Cha, DR; Han, DS; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, SW; Kang, YS; Kim, HK; So, GA, 2004) |
| "A total of 201 patients with IDDM for more than 10 years and 159 patients with IDDM for more than 15 years were randomly selected in our hospital." | 1.30 | Genetic polymorphism of renin-angiotensin system is not associated with diabetic vascular complications in Japanese subjects with long-term insulin dependent diabetes mellitus. ( Iwamoto, Y; Miura, J; Omori, Y; Uchigata, Y; Yokoyama, H, 1999) |
| " Ten db/db mice were given, for 3 months, a solution containing a daily dosage of creatine of 50 mg/kg body weight." | 1.29 | Creatine reduces collagen accumulation in the kidneys of diabetic db/db mice. ( Adamiker, D; Aufricht, C; Fang-Kircher, S; Gialamas, H; Herkner, K; Hoeger, H; Lubec, B; Lubec, G, 1994) |
| "The high prevalence of small LDL in diabetic nephropathy was also observed even when hypertriglyceridemic or hypertensive subjects were excluded from each group." | 1.29 | High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. ( Adachi, M; Ebara, T; Hirano, T; Kurokawa, M; Nagano, S; Naito, H; Yoshino, G, 1996) |
| "In regard to diabetic complications, recurrence of diabetic nephropathy was common, but only two patients lost graft function solely for this reason." | 1.28 | Long-term survival following kidney transplantation in 100 type I diabetic patients. ( Fryd, DS; Goetz, FC; Kaufman, DB; Kennedy, WR; Mauer, SM; McHugh, L; Najarian, JS; Navarro, X; Ramsay, RC; Sutherland, DE, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.90) | 18.7374 |
| 1990's | 3 (7.14) | 18.2507 |
| 2000's | 14 (33.33) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaguchi, S | 1 |
| Hamano, T | 1 |
| Oka, T | 1 |
| Doi, Y | 1 |
| Kajimoto, S | 1 |
| Sakaguchi, Y | 1 |
| Suzuki, A | 1 |
| Isaka, Y | 1 |
| Pitt, B | 1 |
| Agarwal, R | 1 |
| Anker, SD | 1 |
| Ruilope, LM | 1 |
| Rossing, P | 1 |
| Ahlers, C | 1 |
| Brinker, M | 1 |
| Joseph, A | 1 |
| Lambelet, M | 1 |
| Lawatscheck, R | 1 |
| Filippatos, GS | 1 |
| Huang, Q | 1 |
| Fei, X | 1 |
| Zhan, H | 1 |
| Gong, J | 1 |
| Zhou, J | 1 |
| Zhang, Y | 2 |
| Ye, X | 1 |
| Song, Y | 1 |
| Ma, J | 1 |
| Wu, X | 1 |
| Ding, K | 1 |
| Li, Z | 1 |
| Lu, Y | 1 |
| Sun, L | 1 |
| Park, CH | 1 |
| Hiratani, K | 1 |
| Natazuka, T | 1 |
| Yokozawa, T | 1 |
| Terai, K | 1 |
| Jin, D | 1 |
| Watase, K | 1 |
| Imagawa, A | 1 |
| Takai, S | 1 |
| Said, E | 1 |
| Zaitone, SA | 1 |
| Eldosoky, M | 1 |
| Elsherbiny, NM | 1 |
| Zhou, Y | 1 |
| Qi, C | 1 |
| Li, S | 2 |
| Shao, X | 1 |
| Mou, S | 1 |
| Ni, Z | 1 |
| Lee, J | 1 |
| Chu, C | 1 |
| Guzman, D | 1 |
| Fontil, V | 1 |
| Velasquez, A | 1 |
| Powe, NR | 1 |
| Tuot, DS | 1 |
| Wang, J | 1 |
| Gao, Y | 1 |
| Ma, M | 1 |
| Li, M | 1 |
| Zou, D | 1 |
| Yang, J | 1 |
| Zhu, Z | 1 |
| Zhao, X | 1 |
| Zhao, C | 1 |
| Luo, Q | 1 |
| He, F | 1 |
| Peng, F | 1 |
| Xia, X | 1 |
| Huang, F | 1 |
| Yu, X | 1 |
| Yeh, WJ | 1 |
| Yang, HY | 1 |
| Chen, JR | 1 |
| Xu, J | 1 |
| Lee, ES | 1 |
| Baek, SH | 1 |
| Ahn, SY | 1 |
| Kim, S | 1 |
| Na, KY | 1 |
| Chae, DW | 1 |
| Chin, HJ | 1 |
| Saravanan, S | 1 |
| Pari, L | 1 |
| Shi, X | 1 |
| Niu, H | 1 |
| Wang, R | 1 |
| Shen, J | 2 |
| Zhou, S | 1 |
| Yang, H | 1 |
| Wang, S | 1 |
| Wu, J | 1 |
| Xia, JF | 1 |
| Hu, P | 1 |
| Liang, QL | 1 |
| Zou, TT | 1 |
| Wang, YM | 1 |
| Luo, GA | 1 |
| Magee, GM | 1 |
| Hunter, SJ | 1 |
| Cardwell, CR | 1 |
| Savage, G | 1 |
| Kee, F | 1 |
| Murphy, MC | 1 |
| Fogarty, DG | 1 |
| Cherney, DZ | 1 |
| Scholey, JW | 1 |
| Daneman, D | 1 |
| Dunger, DB | 1 |
| Dalton, RN | 1 |
| Moineddin, R | 1 |
| Mahmud, FH | 1 |
| Dekker, R | 1 |
| Elia, Y | 1 |
| Sochett, E | 1 |
| Reich, HN | 1 |
| Bishnoi, HK | 1 |
| Mahadevan, N | 1 |
| Balakumar, P | 1 |
| Sun, H | 1 |
| Ge, N | 1 |
| Shao, M | 1 |
| Cheng, X | 1 |
| Li, Y | 1 |
| Goto, A | 1 |
| Suzuki, H | 1 |
| Kanno, Y | 1 |
| Ikeda, N | 1 |
| Nakamoto, H | 1 |
| Okada, H | 1 |
| Sugahara, S | 1 |
| Marre, M | 1 |
| Garcia Puig, J | 1 |
| Kokot, F | 1 |
| Fernandez, M | 1 |
| Jermendy, G | 1 |
| Opie, L | 1 |
| Moyseev, V | 1 |
| Scheen, A | 1 |
| Ionescu-Tirgoviste, C | 1 |
| Saldanha, MH | 1 |
| Halabe, A | 1 |
| Williams, B | 1 |
| Mion, D | 1 |
| Ruiz, M | 1 |
| Hermansen, K | 1 |
| Tuomilehto, J | 1 |
| Finizola, B | 1 |
| Pozza, G | 1 |
| Chastang, C | 1 |
| Ollivier, JP | 1 |
| Amouyel, P | 1 |
| Asmar, R | 1 |
| BERMAN, LB | 1 |
| EBRAHIMI, A | 1 |
| Han, SY | 1 |
| So, GA | 1 |
| Jee, YH | 1 |
| Han, KH | 1 |
| Kang, YS | 1 |
| Kim, HK | 1 |
| Kang, SW | 1 |
| Han, DS | 1 |
| Han, JY | 1 |
| Cha, DR | 1 |
| Kjeldsen, SE | 1 |
| Os, I | 1 |
| Hedner, T | 1 |
| Himmelmann, A | 1 |
| Wihler, C | 1 |
| Schäfer, S | 1 |
| Schmid, K | 1 |
| Deemer, EK | 1 |
| Münch, G | 1 |
| Bleich, M | 1 |
| Busch, AE | 1 |
| Dingermann, T | 1 |
| Somoza, V | 1 |
| Baynes, JW | 1 |
| Huber, J | 1 |
| Menini, S | 1 |
| Amadio, L | 1 |
| Oddi, G | 1 |
| Ricci, C | 1 |
| Pesce, C | 1 |
| Pugliese, F | 1 |
| Giorgio, M | 1 |
| Migliaccio, E | 1 |
| Pelicci, P | 1 |
| Iacobini, C | 1 |
| Pugliese, G | 1 |
| Biesenbach, G | 1 |
| Schmekal, B | 1 |
| Pieringer, H | 1 |
| Janko, O | 1 |
| Kim, CS | 1 |
| Sohn, EJ | 1 |
| Kim, YS | 1 |
| Jung, DH | 1 |
| Jang, DS | 1 |
| Lee, YM | 1 |
| Kim, DH | 1 |
| Kim, JS | 1 |
| Rigalleau, V | 1 |
| Lasseur, C | 1 |
| Raffaitin, C | 1 |
| Beauvieux, MC | 1 |
| Barthe, N | 1 |
| Chauveau, P | 1 |
| Combe, C | 1 |
| Gin, H | 1 |
| Williams, ME | 1 |
| Bolton, WK | 1 |
| Khalifah, RG | 1 |
| Degenhardt, TP | 1 |
| Schotzinger, RJ | 1 |
| McGill, JB | 1 |
| Winiarska, K | 1 |
| Malinska, D | 1 |
| Szymanski, K | 1 |
| Dudziak, M | 1 |
| Bryla, J | 1 |
| Selam, JL | 1 |
| Giraud, P | 1 |
| Mirouze, J | 1 |
| Lubec, B | 1 |
| Aufricht, C | 1 |
| Herkner, K | 1 |
| Hoeger, H | 1 |
| Adamiker, D | 1 |
| Gialamas, H | 1 |
| Fang-Kircher, S | 1 |
| Lubec, G | 1 |
| Hirano, T | 1 |
| Naito, H | 1 |
| Kurokawa, M | 1 |
| Ebara, T | 1 |
| Nagano, S | 1 |
| Adachi, M | 1 |
| Yoshino, G | 1 |
| Miura, J | 1 |
| Uchigata, Y | 1 |
| Yokoyama, H | 1 |
| Omori, Y | 1 |
| Iwamoto, Y | 1 |
| Brenner, BM | 1 |
| Cooper, ME | 1 |
| de Zeeuw, D | 1 |
| Keane, WF | 1 |
| Mitch, WE | 1 |
| Parving, HH | 1 |
| Remuzzi, G | 1 |
| Snapinn, SM | 1 |
| Zhang, Z | 1 |
| Shahinfar, S | 1 |
| Zilin, S | 1 |
| Naifeng, L | 1 |
| Bicheng, L | 1 |
| Jiping, W | 1 |
| Najarian, JS | 1 |
| Kaufman, DB | 1 |
| Fryd, DS | 1 |
| McHugh, L | 1 |
| Mauer, SM | 1 |
| Ramsay, RC | 1 |
| Kennedy, WR | 1 |
| Navarro, X | 1 |
| Goetz, FC | 1 |
| Sutherland, DE | 1 |
| Spesivtseva, VG | 1 |
| Mamaeva, GG | 1 |
| Starosel'tseva, LK | 1 |
| Kozlova, EG | 1 |
| Muth, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Dia[NCT02540993] | Phase 3 | 5,734 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus a[NCT02545049] | Phase 3 | 7,352 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| Thymol Administration Effects on Netrin-1 Serum Concentration on Obese Patients[NCT05427721] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes[NCT01581476] | Phase 3 | 443 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1263 |
| Placebo | 1321 |
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02540993)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 219 |
| Placebo | 244 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02540993)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.655 |
| Placebo | 0.952 |
Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 367 |
| Placebo | 420 |
Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 252 |
| Placebo | 326 |
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 504 |
| Placebo | 600 |
Number of participants with first occurrence of a hospitalization event were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1573 |
| Placebo | 1605 |
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02545049)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 333 |
| Placebo | 370 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02545049)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.624 |
| Placebo | 0.922 |
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 458 |
| Placebo | 519 |
Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 108 |
| Placebo | 139 |
Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 350 |
| Placebo | 395 |
8 trials available for creatine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Therapeutic effect of Chinese prescription Kangen-karyu in patients with diabetic nephropathy.
Topics: Aged; Creatine; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Glomerular Filtration Rate; G | 2020 |
Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function.
Topics: Aged; Albuminuria; Anti-Inflammatory Agents; Calcium Dobesilate; Chronic Disease; Creatine; Cross-Se | 2018 |
Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria.
Topics: Adolescent; Albuminuria; Biomarkers; Chemokines; Child; Creatine; Cytokines; Diabetes Mellitus, Type | 2012 |
Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Circadian Rhythm; Creatine; | 2002 |
Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
Topics: Adult; Aged; Albuminuria; Clinical Protocols; Creatine; Delayed-Action Preparations; Diabetes Mellit | 2003 |
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Topics: Adolescent; Adult; Aged; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ne | 2007 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
34 other studies available for creatine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Low-grade proteinuria and atherosclerotic cardiovascular disease: A transition study of patients with diabetic kidney disease.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Creatine; Diabetic Nephropathies; Female; Glomerular | 2022 |
Urinary N-acetyl-β-d-glucosaminidase-creatine ratio is a valuable predictor for advanced diabetic kidney disease.
Topics: Acetylglucosaminidase; Biomarkers; Creatine; Diabetes Mellitus; Diabetic Nephropathies; Humans; Kidn | 2023 |
Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Topics: Bayes Theorem; Cardiovascular Diseases; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2023 |
Mechanism of Albuminuria Reduction by Chymase Inhibition in Diabetic Mice.
Topics: Albuminuria; Animals; Biomarkers; Blood Glucose; Body Weight; Chymases; Creatine; Diabetes Mellitus, | 2020 |
Nifuroxazide, a STAT3 inhibitor, mitigates inflammatory burden and protects against diabetes-induced nephropathy in rats.
Topics: Animals; Anti-Inflammatory Agents; Blood Urea Nitrogen; Creatine; Diabetes Mellitus, Experimental; D | 2018 |
Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Asian People; Black or African American; Cr | 2019 |
Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice.
Topics: Albuminuria; Animals; Collagen Type IV; Creatine; Diabetic Nephropathies; Fibronectins; Fibrosis; Ge | 2013 |
Establishing HbA1c -mean blood glucose formulae for patients on continuous ambulatory peritoneal dialysis.
Topics: Adult; Blood Glucose; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephr | 2014 |
Soy β-conglycinin retards progression of diabetic nephropathy via modulating the insulin sensitivity and angiotensin-converting enzyme activity in rats fed with high salt diet.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, Plant; Blood Glucose; Creatine; Diabeti | 2014 |
Effect of bilirubin on triglyceride synthesis in streptozotocin-induced diabetic nephropathy.
Topics: Animals; Bilirubin; Cell Line, Tumor; Creatine; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2014 |
Protective effect of thymol on high fat diet induced diabetic nephropathy in C57BL/6J mice.
Topics: Animals; Anti-Infective Agents; Blood Glucose; Creatine; Diabetic Nephropathies; Diet, High-Fat; Ins | 2016 |
[Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus].
Topics: Adult; Aspartic Acid; Case-Control Studies; Cerebrum; Choline; Cognition; Cognition Disorders; Creat | 2016 |
Correlations of creatine and six related pyrimidine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients.
Topics: Aged; Chromatography, High Pressure Liquid; Creatine; Cytidine; Cytosine; Deoxyuridine; Diabetes Mel | 2010 |
Identifying additional patients with diabetic nephropathy using the UK primary care initiative.
Topics: Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progre | 2010 |
The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Creatine | 2012 |
Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats.
Topics: Animals; Blotting, Western; Collagen Type IV; Creatine; Diabetes Mellitus, Experimental; Diabetic Ne | 2013 |
Diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
EXPERIENCES WITH FUROSEMIDE IN RENAL DISEASE.
Topics: Biomedical Research; Blood Urea Nitrogen; Creatine; Creatinine; Diabetic Nephropathies; Diuretics; D | 1965 |
Effect of retinoic acid in experimental diabetic nephropathy.
Topics: Animals; Cell Line; Chemokine CCL2; Creatine; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2004 |
Renal hypertensive target organ damage--new evidence emerges in diabetics and smokers.
Topics: Albuminuria; Cardiovascular Diseases; Creatine; Diabetic Nephropathies; Female; Humans; Hypertension | 2004 |
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Ascorbic Acid; Blood Glucose; Chromatography, Hig | 2005 |
Deletion of p66Shc longevity gene protects against experimental diabetic glomerulopathy by preventing diabetes-induced oxidative stress.
Topics: Adaptor Proteins, Signal Transducing; Albuminuria; Animals; Apoptosis; Caspase 3; Collagen Type IV; | 2006 |
Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy.
Topics: Aged; Blood Pressure; Cholesterol; Creatine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabe | 2006 |
Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
Topics: Administration, Oral; Animals; Blood Glucose; Collagen Type IV; Creatine; Diabetes Mellitus, Experim | 2007 |
Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group.
Topics: Aged; Albuminuria; Blood Glucose; Creatine; Diabetic Nephropathies; Diet; Diet, Diabetic; Female; Gl | 2007 |
Lipoic acid ameliorates oxidative stress and renal injury in alloxan diabetic rabbits.
Topics: Animals; Antioxidants; Blood Glucose; Creatine; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2008 |
The point of no-return for the diabetic kidney is beyond clinical proteinuria.
Topics: Adult; Creatine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Glomerular Filtration Rate; Huma | 1984 |
Creatine reduces collagen accumulation in the kidneys of diabetic db/db mice.
Topics: Animals; Binding Sites; Blood Glucose; Body Weight; Collagen; Creatine; Diabetes Mellitus, Experimen | 1994 |
High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Apoproteins; Blood Glucose; Body Mass Index; Carrier Proteins; Cholesterol Ester | 1996 |
Genetic polymorphism of renin-angiotensin system is not associated with diabetic vascular complications in Japanese subjects with long-term insulin dependent diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensinogen; Blood Pressure; Cohort Studies; Creatine; Diabetes Mellitus, Ty | 1999 |
The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy.
Topics: Animals; Biomarkers; Calibration; Case-Control Studies; Chromatography, High Pressure Liquid; Creati | 2001 |
Long-term survival following kidney transplantation in 100 type I diabetic patients.
Topics: Age Factors; Cadaver; Creatine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Neuropat | 1989 |
[Early detection of nephroangiopathy in patients with diabetes mellitus and approaches to its correction].
Topics: Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neph | 1989 |
Diuretic properties of furosemide in renal disease.
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aged; Amyloidosis; Blood Urea Nitrogen; Creatine; Diabetic | 1968 |